Navigation Links
AstraZeneca and DNDi to collaborate on drug screening for neglected tropical diseases
Date:4/12/2012

AstraZeneca and the Drugs for Neglected Diseases initiative (DNDi) today announce an agreement to collaborate on drug-compound screening for leishmaniasis, Chagas disease, and sleeping sickness, three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide. Novel drug candidates to emerge from this collaboration will bolster the drug development pipeline for new medicines urgently needed by millions of patients.

In the new partnership, AstraZeneca will provide to DNDi 15,000 compounds that have the potential for activity against leishmaniasis, Chagas disease, and sleeping sickness. The screening activities, coordinated by DNDi, will be performed at Institut Pasteur Korea (IPK). If active compounds against any of the three diseases are identified as 'hits', DNDi and AstraZeneca will jointly assess their potential as starting points for future medicines.

'As a global pharmaceutical company which conducts a significant amount of infectious disease research, AstraZeneca recognizes the urgent need to deliver new medicines for people who suffer from neglected tropical diseases. Sharing science beyond our own labs with leading organizations like DNDi is a great way to tackle these complex diseases that have gone unchecked for far too long', said Manos Perros, Head of the AstraZeneca Infection Innovative Medicines Unit.

The visceral form of leishmaniasis has one of the highest death rates of all NTDs, killing up to 60,000 people each year mainly in Africa and South Asia. The cutaneous form disables and deforms 1.5 million people throughout the Middle East and Latin America. Chagas disease infects approximately 8 million people and is the leading parasitic killer in the Americas, causing approximately 12,000 deaths each year. Sleeping sickness (human African trypanosomiasis) threatens millions in 36 countries in sub-Saharan Africa and, like the visceral form of leishmaniasis, is fatal if left untreated.

'We welcome AstraZeneca as a new partner in our ongoing efforts to access the compounds necessary to boost the development of much-needed medicines for the world's most neglected patients, including those afflicted with leishmaniasis, Chagas disease, and sleeping sickness', says Dr Bernard Pcoul, Executive Director of DNDi. 'This first agreement with AstraZeneca gives us a solid basis to build a fruitful collaboration and access promising new drug compounds for these and other neglected diseases.'

This agreement follows on the commitments announced at a landmark meeting in London on January 30, 'Uniting to Combat NTDs', where a range of public and private partners gathered in a coordinated push to support the WHO's control and eliminations goals for 10 of the 17 neglected tropical diseases (NTDs) by 2020.


'/>"/>
Contact: Oliver Yun
oyun@dndi.org
646-266-5216
Drugs for Neglected Diseases Initiative
Source:Eurekalert

Related medicine news :

1. ECNP expresses concern at AstraZeneca neuroscience pull-out
2. AstraZeneca and UCL to collaborate to develop regenerative medicines for diabetic retinopathy
3. AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims
4. Freedland Russo Announces $520 Million Settlement Against AstraZeneca
5. UNC scientists collaborate to find first major genetic mutation associated with hereditary prostate cancer risk
6. Kessler Foundation and USC collaborate on clinical virtual reality for disability research
7. Penn collaborates on $8 million Barretts esophagus research network
8. Young Children Collaborate Better Than Chimps
9. Scientists in Singapore and Europe to collaborate
10. MDA, Walgreens collaborate to provide flu shots at more than 8,000 locations
11. Scripps Health and Sanford-Burnham to collaborate to advance new cancer treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... The ... among the top five firms in the “2015/2016 Best in KLAS: Software and ... Staffing. KLAS is a research and insights firm on a global mission to ...
(Date:2/11/2016)... FL (PRWEB) , ... February 11, 2016 , ... ... and advocates will discuss how to improve care by making data on heart ... heart disease. The Summit on Transparency and Public Reporting of Pediatric and Congenital ...
(Date:2/11/2016)... ... , ... In a new paper published in the latest ... J. Rohrich, and colleagues, examine and underscore the importance of upper lateral cartilage ... addressing this vital area. , The upper lateral cartilage in rhinoplasty, refers to ...
(Date:2/11/2016)... ... February 11, 2016 , ... veEDIS Clinical ... technology, with highly adaptable algorithms, has been updated to help Emergency Department physicians ... symptoms consistent with Zikas and a travel history to affected regions, or potential ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... trainer and author Ray Clarke poses a question as a challenge for his ... his book, "Being in the Being" (published by Partridge Singapore), Clarke explores the ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... -- PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for ... Company also filed its Quarterly Report on Form 10-Q for ... and Exchange Commission today. --> ... --> --> Net sales for the three ... to $5.4 million from $2.8 million for the three months ...
(Date:2/11/2016)... 11, 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ... the lives of pets, today announced the submission to ... Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  ... of Zimeta for the control of pyrexia (fever) in ... --> --> The Chemistry, Manufacturing, ...
(Date:2/11/2016)... , Feb. 11, 2016  Governor Andrew M. ... will create 1,400 jobs throughout Western New ... partnership with the SUNY Polytechnic Institute, includes a major ... Building in Buffalo , as well ... manufacturing facility in Dunkirk . The ...
Breaking Medicine Technology: